University of Maryland, Baltimore;The United States Of America As Represented By The Department Of Veterans Affairs
发明人:
申请号：
EP16178879.9
公开号：
EP3103451A1
申请日:
2008.01.11
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
The present invention provides a pharmaceutical composition comprising an inhibitor of an NCCa-ATP channel and a pharmaceutically acceptable carrier for use in a method of preventing or reducing ischemic damage in one or more organs or tissues selected from kidney, whereinthe inhibitor is administered as a loading dose followed by a constant infusion, orthe inhibitor is delivered in a dosage of less than 3.5 mg per day, orthe inhibitor is delivered at a dosage of less than 0.8 mg/kg body weight within a 24 hour period.
